A solid-state approach to enable early development compounds: Selection and animal bioavailability studies of an itraconazole amorphous solid dispersion

Journal of Pharmaceutical Sciences

Volumn 99, Issue 9, 2010, Pages 3901-3922

  Engers, David ^a   Teng, Jing ^a   Jimenez Novoa, Jonathan ^b   Gent, Philip ^b   Hossack, Stuart ^b   Campbell, Cheryl ^b   Thomson, John ^b   Ivanisevic, Igor ^a   Templeton, Alison ^b   Byrn, Stephen ^c   Newman, Ann ^a  

^a Aptuit Inc   (United States)

^b An Evotec Company   (United Kingdom)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Bioavailability; Glass transition; Itraconazole; Phase separation; Solid dispersion; Spray drying; X ray amorphous; X ray powder diffraction

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE; POVIDONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STORAGE; EVAPORATION; EXPERIMENTAL DOG; FREEZE DRYING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SCALE UP; SOLID STATE; X RAY POWDER DIFFRACTION;

EID: 77956384896     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22233     Document Type: Article

References (95)

1. Innovation or stagnation? challenge and opportunity on the critical path to new medical products, FDA Report, March 2004.
2. Garnie J-P. 2008. Rebuilding the R&D Engine in Big Pharma, Harvard Business Review, May: 69-76.
3. Bonabeau E, Bodick N, Armstrong RW. 2008. A more rational approach to new-product development. Harvard Business Review, March: 1-6.
4. Hariharan M, Ganorkar LD, Amidon GE, Cavallo A, Gatti P, Hageman MJ, Choo I, Miller JL, Shah UJ. 2003. Reducing the time to develop and manufacture formulations for first oral dose in humans. Pharm Tech 27:68-84.
5. Henck J-O, Byrn SR. 2007. Designing a molecular delivery system within a preclinical timeframe. Drug Discov Today 12:189-199. (Pubitemid 46316891)
6. Huang L-F, Tong W-Q. 2004. Solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev 56:321-334.
7. Anon 2006 GAO report to Congress, New Drug Development, GAO-07-49, November.
8. Ku MS. 2010. Salt and polymorph selection strategy based on the biopharmaceutical classification system for early pharmaceutical development. Am Pharm Rev 13:22-30.
9. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
10. Wu CY, Benet LZ. 2005. Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
11. ICH Harmonized Tripartate Guidelines. Pharmaceutical Development. Q8 (R1), November 2008.
12. FDA Guidance for Industry. PAT - A framework for innovative pharmaceutical development, manufacturing, and quality assurance, September 2004.
13. Sheen P-C, Khetarpal VK, Cariola CM, Rowlings CE. 1995. Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int J Pharm Sci 188:221-227.
14. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability. J Pharm Sci 98:2549-2572.
15. Brewster ME, Neekens P. Peeters J. 2007. Solubilization of itraconazole as a function of cyclodextrin structural space. J Incl Phenom Macro 57:561-566.
16. Gilis PMV, De Condé VFV, Vandecruys RPG. 1997. Beads having a core coated with an antifungal and a polymer. US Patent 5,633,015.
17. François MKJ, Dries WMAC. 1998. Oral formulations of an antifungal. US Patent 5,707,975.
18. Vaughn JM, McConville JT, Burgess D, Peters JI, Johnston KP, Talbert RL, Williams RO. 2006. Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 63:95-102.
19. Mellaerts R, Mols R, Jammaer JAG, Aerts CA, Annaert P, Van Humbeeck J, Van Den Mooter G, Augustijns P, Martens JA. 2008. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm 69:223-230.
20. Swaminathan S, Vavia PR, Trotta F, Torne S. 2007. Formulation of betacyclodextrin based nanosponges of itraconazole. J Incl Phenom Macro 57:89-94.
21. Hong J-Y, Kim J-K, Song Y-K, Park J-S, Kim C-K. 2006. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release 110:332-338.
22. Jung H, Kim H-M, Choy YB, Hwang S-J, Choy J-H. 2008. Laponite-based nanohybrid for enhanced solubility and controlled release of itraconazole. Int J Pharm 349:283-290.
23. Verreck G, Chun I, Rosenblatt J, Peeters J, Van Dijck A, Mensch J, Noppe M, Brewster ME. 2003. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J Control Release 92:349-360.
24. Brewster ME, Verreck G, Chun I, Rosenblatt J, Mensch J, Van Dijck A, Noppe M, Arien A, Bruining M, Peeters J. 2004. The use of polymer-based electrospun nanofibers containing amorphous drug dispersions for the delivery of poorly water-soluble pharmaceuticals. Pharmazie 59:387-391.
25. Rasenack N, Muller BW. 2002. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res 19:1894-1900. (Pubitemid 36016039)
26. Sinswat P, Gao X, Yacaman MJ, Willliams RO, Johnston KP. 2005. Stabilizer choice for rapid dissolving high potency itraconazole particles formed by evaporative precipitation into aqueous solution. Int J Pharm 302:113-124.
27. Kapsi SG, Ayres JW. 2001. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm 2229:193-203.
28. Wang X, Michoel A, Van den Mooter G. 2004. Study of the phase behavior of polyethylene glycol 6000-itraconazole solid dispersions using DSC. Int J Pharm 272:181-187.
29. Jung J-Y, Yoo SD, Lee S-H, Kim K-H, Yoon S-D, Lee K-H. 1999. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm 87:209-218.
30. Showdary KP, Rao SS. 2000. Dissolution rate and formuation studies on solid dispersions of itraconazole. Indian J Pharm Sci 62:471-474.
31. Six K, Berghmans H, Leuner C, Dressman J, Van Werde K, Mullens J, Benoist L, Thimon M, Meubat L, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, part II. Pharm Res 20:1047-1054. (Pubitemid 36774276)
32. 2 as a reversible plasticizer and foaming agent on the hot stage extrusion of itraconazole with EC 20 cps. J Supercritical Fluids 40:153-162.
33. Six K, Murphy J, Weuts II, Craig DQM, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2003. Identification of phase separation in solid dispersion of itraconazole and Eudragit® E100 using microthermal analysis. Pharm Res 20:135-138.
34. Six K, Leuner C, Dressman J, Verreck G, Peeters J, Biaton N, Augustijns P, Kinget R, Van den Mooter G. 2002. Thermal properties of hot-stage extrudates of itraconazole and Eudragit E100. Phase separation and polymorphism. J Therm Anal Calorim 68:591-601.
35. Van den Mooter G, Weuts I, De Ridder T, Blaton N. 2006. Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int J Pharm 316:1-6. (Pubitemid 43765697)
36. Verreck G, Decorte A, Heymans K, Adriaensen J, Cleeren D, Jacobs A, Liu D, Tomasko D, Arien A, Peeters J, Rombaut P, Van den Mooter G, Brewster ME. 2005. Eur J Pharm Sci 26:349-358.
37. Janssens S, Novoa de Armas H, Remon JP, Van den Mooter G. 2007. The use of a new hydrophilic polymer, Kollicoat IR®, in the formulation of solid dispersions of itraconazole. Eur J Pharm Sci 30:288-294.
38. Overhoff KA, Moreno A, Miller SA, Johnston KP, Williams RO. 2007. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing. Int J Pharm 336:122-132.
39. Six K, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2004. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci 93:124-131. (Pubitemid 38081820)
40. Six K, Daems T, De Hoon J, Van Hecken A, Depre M, Bouche M-P, Prinsen P, Verreck G, Peeters J, Brewster ME, Van den Mooter G. 2005. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci 24:179-186.
41. Ramball B, Verreck G, Baert L, Massart DL. 2003. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev Ind Pharm 29:641-652.
42. Janssens S, Nagels S, Novoa de Armas H, D'Autry W, Van Schepdael A, Van den Mooter G. 2008. Formulation and characterization of ternary solid dispersion made up of itraconazole and two excipients, TPGS 1000 and PVPVA64, that were selected based on a supersaturation screening study. Eur J Pharm Biopharm 69:158-166.
43. Janssens S, Novoa de Armas H, Roberts CJ, Van den Mooter G. 2008. Characterization of ternary solid dispersions of itraconazole, PEG 6000 and HPMC 2910 E5. J Pharm Sci 97:2110-2120.
44. Janssens S, Roberts C, Smith EF, Van den Mooter G. 2008. Physical stability of ternary solid dispersion of itraconazole in polyethylene glycol 6000/hydroxypropylmethylcellulose 2910 E5 blends. Int J Pharm 355:100-107.
45. Wang X, Michoel A, Van den Mooter G. 2005. Solid state characteristics of ternary solid dispersion composed of PVPVA64. Myrj 52 and itraconazole. Int J Pharm 303:54-61. (Pubitemid 41318021)
46. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster M. 2003. Characterisation of solid dispersions of itraconazole and HPMC prepared by melt extrusion part-I. Int J Pharm 251:165-174.
47. Ye G, Wang S, Heng PWS, Chen L, Wang C. 2007. Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization. Int J Pharm 337:80-87.
48. Newman A, Engers D, Bates S, Ivanisevic I, Kelly RC, Zografi G. 2008. Characterization of API: Polymer mixtures using X-ray powder diffraction. J Pharm Sci 97:4840-4856.
49. Guidance on the operation of the animals (Scientific Procedures) Act 1986. London: HMSO, March 2000.
50. 1H-1,2,4-triazol-1-ylmethyl)- 1,3-dioxolan-4-yl]methoxy}phenyl)- lpiperazinyl]phenyl}-2,4-dihydro-3H-1,2,4- triazol-3-one (Itraconazole). Acta Crystallogr C C52:2225-2229.
51. Six K, Verreck G, Peeters J, Augustijns P, Kinget R, Van den Mooter G. 2001. Characterization of glassy itraconazole: A comparative study of its molecular mobility below Tg with that of structural analogues using MTDSC. Int J Pharm 213:163-173.
52. At the time of this study, a suitable laboratory spray dryer was not available. Our laboratory has since acquired a Büchi B-290 Mini Spray Dryer for this purpose.
53. Hancock B, Shamblin S, Zografi G. 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 12:799-806.
54. Song M, Hammiche A, Pollock HM, Hourston DJ, Reading M. 1996. Modulated differential scanning calorimetry: 4. Miscibility and glass transition behavior in poly(methyl methacrylate) and poly(epichlorohydrin) blends. Polymer 37:5661-5665.
55. Krause S, Iskander M. 1977. Phase separation in styrene-amethyl styrene block copolymers. In: Klempner D, Frisch KC, editors. Polymer science and technology. New York: Plenum Press. pp 231-243.
56. Aguiar AJ, Krc J, Kinkel AW, Samyn JC. 1967. Effect of polymorphism on the absorption of chloramphenicol palmitate. J Pharm Sci 56:847-853.
57. Wadke DA, Reier GE. 1972. Use of intrinsic dissolution rates to determine thermodynamic parameters associated with phase transitions. J Pharm Sci 61:868-871.
58. Barbanoj MJ, Gich I, Artigas R, Tost D, Moros C, Antonijoan RM, Garcia ML, Mauleon D. 1998. Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses. J Clin Pharm 38:33S-40S.
59. Bak A, Gore A, Yanez E, Stanton M, Tufekcic S, Sysed R, Akrami A, Rose M, Surapaneni D, Bostick T, King A, Neervannan S, Ostovic D, Koparka RA. 2008. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci 97:3942-3956.
60. Singhal D, Curatolo W. 2004. Drug polymorphism and dosage form design: A practical perspective. Adv Drug Deliv Rev 56:335-347. (Pubitemid 38201429)
61. Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 126:13335-13342.
62. Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9:2950-2967.
63. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60.
64. Law D, Schmitt EA, March KC, Everitt EA, Wang W, Fort JJ, Krill SL, Qiu Y. 2004. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations. J Pharm Sci 93:463-570.
65. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chai B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni S. 2008. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: A case study. Mol Pharm 5:981-993.
66. Lakshman JP, Cao Y, Kowalski J, Serajuddin ATM. 2008. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol Pharm 5:994-1002.
67. Klein CE, Chiu Y-L, Awni W, Zhu T, Heuser R, Doan T, Breitenbach J, Morris J, Brun S, Hanna GJ. 2007. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. JAIDS 44:401-410.
68. Garren KW, Rahim S, Marsh K, Morris JB. 2009. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model. J Pharm Sci early view, 10.1002/jps21712.
69. Breitenbach J. 2006. Melt extrusion can bring new benefits to HIV therapy: The example of Kaletra tablets.Am J Drug Deliv 4:61-64.
70. Shanbhag A, Rabel S, Nauka E, Casadevall G, Shivanand P, Eichenbaum G, Mansky P. 2008. Method for screening of solid dispersion formulations of low-solubility compounds - Miniaturization and automation of solvent casting and dissolution testing. Int J Pharm 351:209-218.
71. Byrn SR, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G. 1995. Pharmaceutical solids: A strategic approach to regulatory considerations. Pharm Res 12:945-954.
72. Newman AW, Childs SL, Cowans BA. 2008. Salt and cocrystal form selection. In: Gad SC, editor. Preclinical development handbook: ADME and biopharmaceutical properties. Hoboken: John Wiley and Sons. pp 455-481.
73. Saxena V, Panicucci R, Joshi Y, Garad S. 2009. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. J Pharm Sci 98:1962-1979.
74. Taylor LS, Zografi G. 1997. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14:1691-1698. (Pubitemid 28062912)
75. Huang J, Wigent RJ, Schwartz JB. 2008. Drug-polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethylcellulose binary blend. J Pharm Sci 97:251-262.
76. Shibata Y, Fujii M, Kokudai M, Noda S, Okada H, Kondoh M, Watanabe Y. 2007. Effect of characteristics of compounds on maintenance of an amorphous state in solid dispersion with crospovidone. J Pharm Sci 96:1537-1547.
77. Khougaz K, Clas S-D. 2000. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J Pharm Sci 89:1325-1334.
78. Marsac PJ, Shamblin SL, Taylor LS. 2006. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res 23:2417-2426.
79. Aso Y, Yoshioka S, Kojima S. 2004. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. J Pharm Sci 93:384-391.
80. Friesen DT, Shankar R, Crew M, Smithey CT, Curatolo WJ, Nightingale JAS. 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Mol Pharm 5:1003-1019.
81. Forster A, Hempenstall J, Tucker I, Rades T. 2001. Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm 226:147-161. (Pubitemid 32800790)
82. Chokshi RN, Sandhu HK, Iyer RM, Shah NH, Makcik AW, Zia H. 2005. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hotmelt extrusion processs as a means to manufacture solid dispersion/solution. J Pharm Sci 94:2463-2474.
83. (a) Moser JD, Broyles J, Liu L, Miller E, Wang M. 2008. Enhancing bioavailability of poorly soluble drugs using spray dried solid dispersions Part I. Am Pharm Rev 68-73;
84. (b) Moser JD, Broyles J, Liu L, Miller E, Wang M. 2008. Enhancing bioavailability of poorly soluble drugs using spray dried solid dispersions Part II. Am Pharm Rev 94-99.
85. Bates S, Zografi G, Engers D, Morris K, Crowley K, Newman A. 2006. Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns. Pharm Res 23:2333-2349.
86. Chokshi R, Zia H, Sandhu HK, Shah NH, Malick WA. 2007. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: Pros and cons. Drug Deliv 14:33-45. (Pubitemid 44764457)
87. Joshi HN, Tejwani RW, Davidovich M, Sahasrabudhe VP, Jemal M, Bathala MS, Varia SA, Serajuddin ATM. 2004. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol polysorbate 80 mixture. Int J Pharm 269:251-258.
88. Lakshman JP, Cao Y, Kowalski J, Serajuddin ATM. 2008. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol Pharm 5:994-1002.
89. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
90. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12:1068-1075.
91. DiNunzio J, Brough C, Hughey JR, Miller DA, Williams RO, McGinity JW. 2010. Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol® dispersing. Eur J Pharm Biopharm 74:340-351.
92. Dong Z, Chatterji A, Sandhu H, Choi DS, Chokshi H, Shah N. 2008. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int J Pharm 355:141-149.
93. Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM, Rades T. 2007. Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. Int J Pharm 336:22-34. (Pubitemid 46551551)
94. Yu L. 2001. Amorphous pharmaceutical solids: Preparation characterization and stabilization. Adv Drug Deliv Rev 48:27-42.
95. Yoo SD, Kang E, Shin BS, Jun H, Lee S-H, Lee KC, Lee K-H. 2002. Interspecies comparison of the oral absorption of itraconazole in laboratory animals. Arch Pharm Res 25:387-391.